Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Holders of 5% or more of FATE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Fate Therapeutics Inc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Redmile Group, LLC | 13D/A | 14.90%17.9M shares | 0.00 ppfrom 14.90% | Dec 26, 20242 filings | Jul 3, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 6.90%7.85M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on Fate Therapeutics Inc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20266:21 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −7.64 ppfrom 7.64%Below 5% | Mar 13, 2026 | SEC |
| Aug 14, 20254:30 PM ET | Schonfeld Strategic Advisors LLC | 13G/A | 0.82%937.5K shares | −5.98 ppfrom 6.80%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 202511:30 AM ET | Goldman Sachs Group Incand 1 other | 13G/A | 2.00%2.27M shares | −5.40 ppfrom 7.40%Below 5% | Jun 30, 2025 | SEC |
| Jul 29, 20251:13 PM ET | Vanguard Group Inc | 13G/A | 7.64%8.77M shares | – | Jun 30, 2025 | SEC |
| Jul 3, 20254:01 PM ET | Redmile Group, LLCand 2 others | 13D/A | 14.90%17.9M shares | 0.00 ppfrom 14.90% | Jul 2, 2025 | SEC |
| May 15, 20254:30 PM ET | Schonfeld Strategic Advisors LLC | 13G | 6.80%7.79M shares | New | Mar 31, 2025 | SEC |
| May 9, 202512:27 PM ET | Goldman Sachs Group Incand 1 other | 13G | 7.40%8.49M shares | New | Mar 31, 2025 | SEC |
| Apr 23, 20258:39 PM ET | BlackRock, Inc. | 13G/A | 6.90%7.85M shares | – | Mar 31, 2025 | SEC |
| Dec 26, 20249:00 PM ET | Redmile Group, LLCand 2 others | 13D/A | 14.90%17.8M shares | – | Dec 20, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Fate Therapeutics Inc shares.
No Form 144 notices for Fate Therapeutics Inc are on file.